These results demonstrate that the anti-tumor effects of ADAM17 pharmacological inhibition also involve the targeting of the ADAM17 expressed by cancer cells in addition to the host-associated anti-angiogenic effect observed previously. The gene discussed is ADAM17; the disease is neoplasm.